A significant number of tumors within the RCC “Not otherwise specified (NOS)” category show somatic mutations of TSC2 or activating mutations of MTOR implying that these factors could be distinct tumor drivers [12]. This evidence concerns the gene MTOR and renal cell carcinoma.